Hangzhou Tigermed Consulting (300347.SZ) Earnings Analysis
Hangzhou Tigermed Consulting (300347.SZ) next reports earnings on 2026-08-29, consensus EPS 0.185 CNY. Last quarter (2026-03-30) it missed with EPS -0.15 CNY vs -0.03 CNY est (-400%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E 54.24.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 300347.SZ next report earnings?
| Next earnings date | 2026-08-29 |
|---|---|
| Consensus EPS estimate | 0.185 CNY |
| Revenue estimate | 1.89B |
300347.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-30 | -0.15 CNY | -0.03 CNY | -400% | Miss |
| 2025-10-29 | 0.733 CNY | 0.3406 CNY | +115.2% | Beat |
| 2025-08-28 | 0.2488 CNY | 0.3497 CNY | -28.9% | Miss |
| 2025-04-28 | 0.19 CNY | 0.3004 CNY | -36.8% | Miss |
| 2024-08-28 | 0.3 CNY | 0.5 CNY | -40% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
300347.SZ valuation and analyst view
| Trailing P/E | 54.24 |
|---|---|
| Trailing EPS | 0.94382 CNY |
| Price / book | 1.89 |
| Dividend yield | 0.26% |
| Market cap | 36.37B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Hangzhou Tigermed Consulting (300347.SZ)'s next earnings date?
Hangzhou Tigermed Consulting is next scheduled to report on 2026-08-29, with a consensus EPS estimate of 0.185 CNY and revenue estimate of 1.89B.
Did 300347.SZ beat earnings last quarter?
In its 2026-03-30 report, 300347.SZ posted EPS of -0.15 CNY versus a -0.03 CNY estimate — a miss of 400%.
What is 300347.SZ's earnings track record?
Over the last 5 reported quarters with consensus data, 300347.SZ beat estimates 1 times (20%).
What is 300347.SZ's current P/E ratio and EPS?
300347.SZ trades at a trailing P/E of 54.24 on trailing EPS of 0.9438197774310005 CNY.
What do analysts rate 300347.SZ?
300347.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.